Evidence map›Paper›PMID 36313371›Full record

ArticleFrontiers in pharmacology2022

An exploratory, open-label, randomized, multicenter trial of hachimijiogan for mild Alzheimer's disease.

Mosaburo Kainuma, Shinji Ouma, Shinobu Kawakatsu, Osamu Iritani, Ken-Ichiro Yamashita, Tomoyuki Ohara, Shigeki Hirano, Shiro Suda, Tadanori Hamano, Sotaro Hieda and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Mosaburo KainumaDepartment of Japanese Oriental Medicine, Toyama University Hospital, Toyama, Japan.
Shinji OumaDepartment of Neurology, School of Medicine, Fukuoka University, Fukuoka, Japan.
Shinobu KawakatsuDepartment of Neuropsychiatry, Aizu Medical Center, Fukushima Medical University, Aizuwakamatsu, Japan.
Osamu IritaniDepartment of Geriatric Medicine, Kanazawa Medical University, Kanazawa, Ishikawa, Japan.
Ken-Ichiro YamashitaTranslational Neuroscience Center, Graduate School of Medicine, International University of Health and Welfare, Tochigi, Japan.
Tomoyuki OharaDepartment of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Shigeki HiranoDepartment of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Shiro SudaDepartment of Psychiatry, Jichi Medical University, Tochigi, Japan.
Tadanori HamanoDivision of Neurology, Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Sotaro HiedaDivision of Neurology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Masaaki YasuiDepartment of Neurology, Wakayama Medical University, Wakayama, Japan.
Aoi YoshiiwaDepartment of General Medicine, Oita UniversityFaculty of Medicine, Oita, Japan.
Seiji ShiotaDepartment of General Medicine, Oita UniversityFaculty of Medicine, Oita, Japan.
Masaya HironishiDepartment of Internal Medicine, Wakayama Medical University Kihoku Hospital, Wakayama, Japan.
Kenji Wada-IsoeDepartment of Dementia Medicine, Kawasaki Medical School, Okayama, Japan.
Daiki SasabayashiDepartment of Neuropsychiatry, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Sho YamasakiDepartment of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan.
Masayuki MurataDepartment of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan.
Kouta FunakoshiCenter for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan.
Kouji HayashiDepartment of Rehabilitation, Fukui Health Science University, Fukui, Japan.
Norimichi ShirafujiDivision of Neurology, Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Hirohito SasakiDivision of Neurology, Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Yoshinori KajimotoDepartment of Internal Medicine, Wakayama Medical University Kihoku Hospital, Wakayama, Japan.
Yukiko MoriDivision of Neurology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Michio SuzukiDepartment of Neuropsychiatry, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Hidefumi ItoDepartment of Neurology, Wakayama Medical University, Wakayama, Japan.
Kenjiro OnoDivision of Neurology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Yoshio TsuboiDepartment of Neurology, School of Medicine, Fukuoka University, Fukuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ADAS‐JcogAlzheimer’s diseasecognitive dysfunctionhachimijioganKampo medicine

Identifiers

PMID36313371
PMCPMC9616163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.